Jiangsu Nhwa Pharmaceutical’s Sulpiride Hydrochloride Tablets gain approval

Jiangsu Nhwa Pharmaceutical Co. recently received approval from the National Medical Products Administration for its Sulpiride Hydrochloride Tablets to pass the generic drug quality and efficacy consistency evaluation. The product, a chemical drug, is registered as 100mg.

This approval is expected to boost the company's market competitiveness. Sulpiride Hydrochloride Tablets are used for conditions such as chorea, Tourette's syndrome, senile psychosis, and alcohol intoxication. Jiangsu Nhwa Pharmaceutical invested approximately RMB 5.7 million in research and development for this consistency evaluation project.

The company anticipates this approval will positively impact future operating performance, as products passing this evaluation receive support in medical insurance payments and preferential procurement by medical institutions. However, the company also cautioned investors about potential market sales uncertainties influenced by national policies and market environmental changes.